Drug General Information
Drug ID	D07YHY
Former ID	DIB013013
Drug Name	CR-2093
Drug Type	Small molecular drug
Indication	Intestine cancer [ICD10:C17-C20, C26]		Discontinued in Phase 1	[544899]
Company	Rotta Research Lab SpA
Structure		Download 2D MOL 3D MOL
Formula	C18H25ClN2O4
Canonical SMILES	C(=O)(N[C@@H](C(=O)NCCC(C)(C)C)CCC(=O)O)c1cc(Cl)ccc1
CAS Number	CAS 136374-73-7
PubChem Compound ID	131954
Target and Pathway
Target(s)	Gastrin/cholecystokinin type B receptor	Target Info	Modulator	[533774]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Gastric acid secretion
PANTHER Pathway	CCKR signaling map ST
PathWhiz Pathway	Gastric Acid Production
Reactome	Peptide ligand-binding receptors
	G alpha (q) signalling events
	Gastrin-CREB signalling pathway via PKC and MAPK
WikiPathways	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Secretion of Hydrochloric Acid in Parietal Cells
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 544899	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001442)
Ref 533774	Inhibitory effects of the gastrin receptor antagonist CR2093 on basal, gastrin-stimulated and growth factor-stimulated growth of the rat pancreatic cell line AR42J. Anticancer Drugs. 1994 Oct;5(5):591-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.